{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:28:13Z","timestamp":1783636093020,"version":"3.55.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40119-025-00436-2","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:29:34Z","timestamp":1760074174000},"page":"531-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hitting the Sweet Spot: A Review of SGLT2i in Cardiovascular Medicine"],"prefix":"10.1007","volume":"14","author":[{"given":"Zaid A.","family":"Zayyad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aanya","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Kalagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atreya","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhas Rathna","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deema","family":"Gichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayan A.","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Ene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Dwyer","family":"Kalzuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3964-9619","authenticated-orcid":false,"given":"Adhir R.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"1","key":"436_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12933-017-0654-z","volume":"17","author":"MV Karg","year":"2018","unstructured":"Karg MV, Bosch A, Kannenkeril D, et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol. 2018;17(1):5.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"436_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"T Vasilenko","year":"2020","unstructured":"Vasilenko T, Charytan DM, Wanner C, et al. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):484\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"436_CR3","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317.","journal-title":"Diabetologia"},{"issue":"22","key":"436_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"436_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic B, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. New Engl J Med. 2017;377(7):644\u201357.","journal-title":"New Engl J Med"},{"key":"436_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"436_CR7","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type\u00a02 diabetes. New Engl J Med. 2020;383:1425\u201335.","journal-title":"New Engl J Med"},{"key":"436_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106597","volume":"187","author":"P Paolisso","year":"2023","unstructured":"Paolisso P, Bergamaschi L, Gragnano F, et al. Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI protect registry. Pharmacol Res. 2023;187:106597.","journal-title":"Pharmacol Res"},{"issue":"21","key":"436_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"16","key":"436_CR10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"24","key":"436_CR11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"2","key":"436_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"15","key":"436_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"12","key":"436_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"436_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"436_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","volume":"146","author":"PC Schulze","year":"2022","unstructured":"Schulze PC, Bogoviku J, Westphal J, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation. 2022;146(4):289\u201398.","journal-title":"Circulation"},{"issue":"3","key":"436_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374.","journal-title":"Nat Med"},{"issue":"4","key":"436_CR18","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713\u201322.","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"436_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","volume":"83","author":"ZL Cox","year":"2024","unstructured":"Cox ZL, Collins SP, Hernandez GA, et al. Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol. 2024;83(14):1295\u2013306.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"436_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.tcm.2022.05.005","volume":"33","author":"R Gupta","year":"2023","unstructured":"Gupta R, Maitz T, Egeler D, et al. SGLT2 inhibitors in hypertension: role beyond diabetes and heart failure. Trends Cardiovasc Med. 2023;33(8):479\u201386.","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"436_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type\u00a02 diabetes and hypertension. Diabetes Care. 2015;38(3):420\u20138.","journal-title":"Diabetes Care"},{"issue":"6","key":"436_CR22","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","volume":"68","author":"G Mancia","year":"2016","unstructured":"Mancia G, Cannon CP, Tikkanen I, et al. Impact of empagliflozin on blood pressure in patients with type\u00a02 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension. 2016;68(6):1355\u201364.","journal-title":"Hypertension"},{"issue":"18","key":"436_CR23","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","volume":"143","author":"N Ye","year":"2021","unstructured":"Ye N, Jardine MJ, Oshima M, et al. Blood pressure effects of canagliflozin and clinical outcomes in type\u00a02 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation. 2021;143(18):1735\u201349.","journal-title":"Circulation"},{"issue":"10","key":"436_CR24","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jacep.2023.06.008","volume":"9","author":"MR Abu-Qaoud","year":"2023","unstructured":"Abu-Qaoud MR, Kumar A, Tarun T, et al. Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type\u00a02 diabetes. JACC Clin Electrophysiol. 2023;9(10):2109\u201318.","journal-title":"JACC Clin Electrophysiol"},{"issue":"7","key":"436_CR25","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","volume":"18","author":"GC Fernandes","year":"2021","unstructured":"Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type\u00a02 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18(7):1098\u2013105.","journal-title":"Heart Rhythm"},{"issue":"1","key":"436_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12933-024-02137-x","volume":"23","author":"J Liao","year":"2024","unstructured":"Liao J, Ebrahimi R, Ling Z, et al. Effect of SGLT-2 inhibitors on arrhythmia events: Insight from an updated secondary analysis of > 80,000 patients (the SGLT2i\u2014arrhythmias and sudden cardiac death). Cardiovasc Diabetol. 2024;23(1):8.","journal-title":"Cardiovasc Diabetol"},{"issue":"17","key":"436_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022222","volume":"10","author":"AK Pandey","year":"2021","unstructured":"Pandey AK, Okaj I, Kaur H, et al. Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2021;10(17):e022222.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"436_CR28","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1097\/FJC.0000000000001183","volume":"79","author":"RJ Zheng","year":"2022","unstructured":"Zheng RJ, Wang Y, Tang JN, Duan JY, Yuan MY, Zhang JY. Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type\u00a02 diabetes: a systemic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2022;79(2):e145\u201352.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"436_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/pace.14880","volume":"47","author":"S Zheng","year":"2024","unstructured":"Zheng S, Lai Y, Jiang C, et al. Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Pacing Clin Electrophysiol. 2024;47(1):58\u201365.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"7","key":"436_CR30","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","volume":"31","author":"HD Zhang","year":"2024","unstructured":"Zhang HD, Ding L, Mi LJ, et al. Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis. Eur J Prev Cardiol. 2024;31(7):770\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"436_CR31","doi-asserted-by":"publisher","first-page":"8732","DOI":"10.3390\/ijms24108732","volume":"24","author":"A Di Costanzo","year":"2023","unstructured":"Di Costanzo A, Esposito G, Indolfi C, Spaccarotella CAM. SGLT2 inhibitors: a new therapeutical strategy to improve clinical outcomes in patients with chronic kidney diseases. Int J Mol Sci. 2023;24(10):8732.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"436_CR32","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40265-021-01573-3","volume":"81","author":"L Del Vecchio","year":"2021","unstructured":"Del Vecchio L, Beretta A, Jovane C, Peiti S, Genovesi S. A role for SGLT-2 inhibitors in treating non-diabetic chronic kidney disease. Drugs. 2021;81(13):1491\u2013511.","journal-title":"Drugs"},{"issue":"18","key":"436_CR33","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.2174\/0929867329666220825121304","volume":"30","author":"P Sarafidis","year":"2023","unstructured":"Sarafidis P, Pella E, Kanbay M, Papagianni A. SGLT-2 inhibitors and nephroprotection in patients with diabetic and non-diabetic chronic kidney disease. Curr Med Chem. 2023;30(18):2039\u201360.","journal-title":"Curr Med Chem"},{"issue":"24","key":"436_CR34","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"436_CR35","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"436_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"6","key":"436_CR37","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1097\/HJH.0000000000002776","volume":"39","author":"P Sarafidis","year":"2021","unstructured":"Sarafidis P, Ortiz A, Ferro CJ, et al. Sodium\u2013glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. J Hypertens. 2021;39(6):1090\u20137.","journal-title":"J Hypertens"},{"key":"436_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000546079","volume":"18","author":"Y An","year":"2025","unstructured":"An Y, Zhang H. SGLT-2 inhibitors: a deeper dive into their renal protective properties beyond glycemic control and proteinuria reduction. Am J Nephrol. 2025;18:1\u201313.","journal-title":"Am J Nephrol"},{"issue":"12","key":"436_CR39","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390.","journal-title":"Diabetes Care"},{"issue":"10","key":"436_CR40","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177\u2013232. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.010. (Erratum in: J Am Coll Cardiol. 2019 Sep 10;74(10):1429-1430).","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"436_CR41","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/j.jacc.2022.08.004","volume":"80","author":"EM Isselbacher","year":"2022","unstructured":"Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC\/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;80(24):e223\u2013393.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"436_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","volume":"83","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(1):109\u2013279.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"436_CR43","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.jacc.2024.06.013","volume":"84","author":"A Thompson","year":"2024","unstructured":"Thompson A, Fleischmann KE, Smilowitz NR, et al. 2024 AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;84(19):1869\u2013969.","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"436_CR44","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"1","key":"436_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","volume":"26","author":"TA McDonagh","year":"2024","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2024;26(1):5\u201317.","journal-title":"Eur J Heart Fail"},{"issue":"39","key":"436_CR46","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"1","key":"436_CR47","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2337\/cd17-0119","volume":"36","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Standards of medical care in diabetes-2018 abridged for primary care providers. Clin Diabetes. 2018;36(1):14\u201337.","journal-title":"Clin Diabetes"},{"issue":"Suppl 1","key":"436_CR48","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19-S010","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142019. Diabetes Care. 2019;42(Suppl 1):S103\u201323.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"436_CR49","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc20-S010","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Suppl 1):S111\u201334.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"436_CR50","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc21-S010","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S125\u201350.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"436_CR51","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.2337\/dc22-S010","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142022. Diabetes Care. 2022;45(Suppl 1):S144\u201374.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"436_CR52","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142023. Diabetes Care. 2023;46(Suppl 1):S158\u201390.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"436_CR53","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024. Diabetes Care. 2024;47(Suppl 1):S179\u2013218.","journal-title":"Diabetes Care"},{"issue":"1 Suppl 1","key":"436_CR54","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142025. Diabetes Care. 2025;48(1 Suppl 1):S207\u201338.","journal-title":"Diabetes Care"},{"issue":"15","key":"436_CR55","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","volume":"83","author":"TM Maddox","year":"2024","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, et al. 2024 ACC Expert Consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;83(15):1444\u201388.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"436_CR56","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463\u201376.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"436_CR57","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/dom.12825","volume":"19","author":"D Li","year":"2017","unstructured":"Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type\u00a02 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348\u201355.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"436_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003666","volume":"11","author":"E Chow","year":"2023","unstructured":"Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2023;11(5):e003666.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"436_CR59","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","volume":"5","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Avogaro A. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017;5(9):680\u20131.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"436_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234065","volume":"15","author":"J Heyward","year":"2020","unstructured":"Heyward J, Mansour O, Olson L, Singh S, Alexander GC. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis. PLoS ONE. 2020;15(6):e0234065.","journal-title":"PLoS ONE"},{"issue":"6","key":"436_CR61","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1161\/CIRCULATIONAHA.122.060823","volume":"146","author":"K Umanath","year":"2022","unstructured":"Umanath K, Testani JM, Lewis JB. \u201cDip\u201d in eGFR: stay the course with SGLT-2 inhibition. Circulation. 2022;146(6):463\u20135.","journal-title":"Circulation"},{"issue":"1","key":"436_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jchf.2023.09.013","volume":"12","author":"O Vardeny","year":"2024","unstructured":"Vardeny O. SGLT2 inhibitors and diuresis: a small piece of the puzzle. JACC Heart Fail. 2024;12(1):47\u20139.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"436_CR63","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaccao.2024.08.001","volume":"6","author":"AW Bhatti","year":"2024","unstructured":"Bhatti AW, Patel R, Dani SS, et al. SGLT2i and primary prevention of cancer therapy-related cardiac dysfunction in patients with diabetes. JACC CardioOncol. 2024;6(6):863\u201375.","journal-title":"JACC CardioOncol"},{"issue":"2","key":"436_CR64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","volume":"6","author":"MS Dabour","year":"2024","unstructured":"Dabour MS, George MY, Daniel MR, Blaes AH, Zordoky BN. The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC CardioOncol state-of-the-art review. JACC Cardiooncol. 2024;6(2):159\u201382.","journal-title":"JACC Cardiooncol"},{"key":"436_CR65","unstructured":"Schulze C. Effects of continued administration of empagliflozin in patients with heart failure on active SGLT2 inhibitor treatment admitted for acute decompensated heart failure. clinicaltrials.gov. 2025. Report no. NCT07038356. https:\/\/clinicaltrials.gov\/study\/NCT07038356. Accessed 2025 July 27."},{"key":"436_CR66","unstructured":"Central Hospital, Nancy, France. Effect at 3\u00a0months of early empagliflozin initiation in cardiogenic shock patients on mortality, rehospitalization, left ventricular ejection fraction and renal function. clinicaltrials.gov. 2025. Report no. NCT05879276. https:\/\/clinicaltrials.gov\/study\/NCT05879276. Accessed 2025 July 27."},{"key":"436_CR67","unstructured":"Rajaie Cardiovascular Medical and Research Center. Empagliflozin to prevent post-operative atrial fibrillation. clinicaltrials.gov. 2023. Report no. NCT06124937. https:\/\/clinicaltrials.gov\/study\/NCT06124937. Accessed 2025 July 27."},{"key":"436_CR68","unstructured":"University of Edinburgh. The DAPA-MEMRI trial. clinicaltrials.gov. 2025. Report no. NCT04591639. https:\/\/clinicaltrials.gov\/study\/NCT04591639. Accessed 2025 July 27."},{"key":"436_CR69","unstructured":"Fondazione IRCCS Policlinico San Matteo di Pavia. Potential protective role of SGLT-2 inhibitors for chemotherapy-induced cardiotoxicity. clinicaltrials.gov. 2024. Report no. NCT06341842. https:\/\/clinicaltrials.gov\/study\/NCT06341842. Accessed 2025 July 27."},{"key":"436_CR70","unstructured":"Chang K. SGLT2 inhibitors on clinical outcomes and left ventricular remodeling in type\u00a02 diabetic patients with acute myocardial infarction, a prospective, multi-center registry study. clinicaltrials.gov. 2025. Report no. NCT05770687. https:\/\/clinicaltrials.gov\/study\/NCT05770687. Accessed 2025 July 27."},{"issue":"9","key":"436_CR71","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","volume":"82","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023;82(9):833\u2013955. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.003.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"436_CR72","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263\u2013421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012.","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"436_CR73","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the Task Force of the European Society of Cardiology (ESC); endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024;45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"issue":"36","key":"436_CR74","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538\u2013700. https:\/\/doi.org\/10.1093\/eurheartj\/ehae179.","journal-title":"Eur Heart J"},{"issue":"36","key":"436_CR75","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation: developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","journal-title":"Eur Heart J"},{"issue":"36","key":"436_CR76","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415\u2013537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177.","journal-title":"Eur Heart J"},{"issue":"40","key":"436_CR77","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"SM Al-Khatib","year":"2022","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997\u20134126.","journal-title":"Eur Heart J"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00436-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00436-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00436-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:03:34Z","timestamp":1764954214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00436-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00436-2","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Zaid Zayyad, Neil Gupta, Aanya Roy, Swetha Kalagara, Atreya Mishra, Edward Salem, Suhas Rathna Seshadri, Deema Gichi, Bayan A Hammad, Adriana Ene, Kayla Torres, Stephanie Dwyer Kalzuna, and Adhir R Shroff declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}